{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-010890","form_type":"8-K","ticker":"ELDN","cik":"0001404281","company_name":"Eledon Pharmaceuticals, Inc.","filed_at":"2022-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.538229+00:00","generated_at":"2026-06-25T05:49:56.399415+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eledon reports positive Phase 2a topline results for tegoprubart in ALS patients","bullets":["Tegoprubart met primary safety and tolerability endpoints; no drug-related serious adverse events observed.","Dose-dependent target engagement at 4 and 8 mg/kg; anti-drug antibodies in <5% of samples, low titer.","Pro-inflammatory ALS signature of 32 biomarkers identified; dose-dependent reduction in up to 23 biomarkers.","Trend in slowing ALS progression (ALSFRS slope) vs. PRO-ACT database; study not powered for efficacy.","Reduced biomarkers also associated with IgA nephropathy and kidney transplant rejection (IgA, C3, CXCL9, etc.)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-010890","json":"https://secwatch.observer/filing/0000950170-22-010890.json","markdown":"https://secwatch.observer/filing/0000950170-22-010890.md","text":"https://secwatch.observer/filing/0000950170-22-010890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/0000950170-22-010890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404281/000095017022010890/eldn-20220531.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T05:49:56.399415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}